Cancer remains one of the developed world’s most serious health problems despite recent advances. Beyond traditional chemotherapeutic approaches to treating cancer, one of the newer interventions is to selectively restrict the blood supply that feeds solid tumors.

Israel Lowy Israel Lowy, M.D., Ph.D. VP Clinical Sciences Translational Science and of Oncology

The growth of solid tumors requires the development of new blood vessels, a process called angiogenesis, to sustain the cancer by providing oxygen and nutrients. Regeneron's approach in oncology is focused on anti-angiogenesis - disrupting the flow of blood to tumors by binding particular proteins that stimulate the formation of new blood vessels.

We have several clinical-stage drug candidates in the pipeline that have been developed based on our understanding of angiogenesis. One product candidate, enoticumab (REGN421), binds the protein delta-like ligand factor 4 (Dll4). We have been in the forefront of discovery of a class of vascular targets called angiopoietins, one of which, Angiopoietin 2 (Ang2), is the target of our product candidate nesvacumab (REGN910).

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)